Provention Bio (NASDAQ:PRVB – Get Rating) had its price objective upped by SVB Leerink from $16.00 to $19.00 in a research report report published on Monday morning, MarketBeat reports. They currently have an outperform rating on the stock.
PRVB has been the subject of several other research reports. Chardan Capital upped their price objective on shares of Provention Bio from $24.00 to $30.00 and gave the company a buy rating in a research note on Friday, November 18th. Jefferies Financial Group upped their price objective on shares of Provention Bio from $18.00 to $22.00 and gave the company a buy rating in a research note on Friday, November 18th. Finally, Oppenheimer boosted their target price on shares of Provention Bio from $14.00 to $18.00 and gave the company an outperform rating in a report on Friday, November 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of Buy and an average target price of $21.40.
Provention Bio Trading Up 5.8 %
Shares of NASDAQ PRVB opened at $9.41 on Monday. Provention Bio has a 12-month low of $3.18 and a 12-month high of $9.65. The company has a quick ratio of 7.58, a current ratio of 7.58 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average of $6.65 and a 200 day moving average of $5.13.
Hedge Funds Weigh In On Provention Bio
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.